在急性失偿性心力衰竭中以天然尿素为导向的治疗:最新的系统性审查和元分析
Luciana Gioli-Pereira1,2, Eric Shih Katsuyama3, Christian Ken Fukunaga3
1Department of Cardiology and Intensive Care, Hospital Municipal Dr Gilson de Cássia Marques de Carvalho, Sociedade Beneficente Israelita Brasileira Albert Einstein, São Paulo, Brazil.
Clinical cardiology
|June 4, 2025
概括
对心力衰竭 (HF) 进行尿素 (NP) 指导治疗显示,在12个月内显著的生存益处. 然而,这并没有转化为其他关键结果,使其整体临床影响不确定.
科学领域:
- 心脏病学 心脏病学
- 临床试验 临床试验
- 生物标志物 生物标志物
背景情况:
- 尿素 (NP) 是心力衰竭 (HF) 的确立诊断标记物.
- 在急性不补偿性HF中,NP导向管理的治疗效用仍然不清楚.
- 这项研究解决了围绕NP在治疗指导中的作用的不确定性.
研究的目的:
- 评估NP指导疗法的疗效与急性不补偿性HF的常规护理相比.
- 评估NP指导治疗对死亡率和住院治疗结果的影响.
- 通过元分析综合随机对照试验 (RCT) 的证据.
主要方法:
- 在PubMed,Embase和Cochrane数据库中的系统文献搜索.
- 对9项 randomised controlled trials (RCT) 的元分析,涉及3992名急性不补偿性HF患者.
- 随机效应建模用于评估全因死亡率,心血管死亡率和复合结果.
主要成果:
- 在NP导向治疗中,所有原因的死亡率在时间上有显著的改善 (HR:0.81;95%CI:0.69-0.95).
- 在所有原因死亡率 (RR:0.84;95% CI:0.69-1.01),心血管死亡 (RR:0.91;95% CI:0.78-1.08) 或复合结果 (RR:0.91;95% CI:0.77-1.09) 中没有观察到显著差异.
- 使用I平方来评估异质性,并应用随机效应模型.
结论:
- 在所有原因死亡率的时间到事件分析中,NP导向治疗显示出显著的生存优势.
- 在其他关键终点上缺乏一致的益处表明整体临床影响仍然不确定.
- 可能需要进一步的研究来澄清NP引导治疗在HF管理中的确切作用.
相关概念视频
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:28Mitral Regurgitation IV: Nursing Management
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.